所有图片(1)
别名:
Fmoc-Val-Ala-OH, N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-valyl-L-alanine, L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl-, L-Alanine, N-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl]-
经验公式（希尔记法）:
C23H26N2O5
推荐产品
质量水平
检测方案
≥95%
形式
powder or crystals
颜色
white to off-white
储存温度
2-8°C
SMILES字符串
C(OC(N[C@H](C(N[C@H](C(O)=O)C)=O)C(C)C)=O)C1C=2C(C=3C1=CC=CC3)=CC=CC2
InChI
1S/C26H32N4O6/c1-15(2)22(23(31)29-21(24(32)33)12-7-13-28-25(27)34)30-26(35)36-14-20-18-10-5-3-8-16(18)17-9-4-6-11-19(17)20/h3-6,8-11,15,20-22H,7,12-14H2,1-2H3,(H,29,31)(H,30,35)(H,32,33)(H3,27,28,34)/t21-,22-/m0/s1
应用
Fmoc-Val-Ala-OH is a lysosomally cleavable linker used in construction of antibody-drug conjugates (ADC & Bioconjugation).
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Alain Beck et al.
Nature reviews. Drug discovery, 16(5), 315-337 (2017-03-18)
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门